Please enter the email address you used to register, then we will send you a link to choose a new password
Oppenheimer analyst Suraj Kalia maintains ResMed (NYSE:RMD) with a Outperform and lowers the price target from $205 to $200.
RBC Capital analyst Craig Wong-Pan maintains ResMed (NYSE:RMD) with a Sector Perform and raises the price target from $187 t...
Keybanc analyst Brett Fishbin maintains ResMed (NYSE:RMD) with a Overweight and raises the price target from $227 to $238.
Tech earnings could come to the market’s rescue as traders remain jittery about the outcome of key inflation data due on Friday.
Needham analyst Mike Matson maintains ResMed (NYSE:RMD) with a Buy and raises the price target from $224 to $236.
ResMed (NYSE:RMD) reported quarterly earnings of $2.13 per share which beat the analyst consensus estimate of $1.91 by 11.52 pe...
On CNBC’s "Mad Money Lightning Round," Jim Cramer recommended buying Uber Technologies, Inc. (NYSE: UBER).